Efficacy of Self-hypnosis for Weight Loss in Type 2 Diabetics

Sponsor
Levenson, David I., M.D. (Other)
Overall Status
Completed
CT.gov ID
NCT02769585
Collaborator
(none)
74
2
21

Study Details

Study Description

Brief Summary

Randomized study evaluating self-hypnosis versus certified diabetes educator training for weight loss in type 2 diabetics.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Self-hypnosis
  • Behavioral: CDE training
N/A

Detailed Description

Study Subjects: Approximately 74 type II diabetics will be randomized. Key inclusion criteria: overweight (BMI≥25), motivated to lose weight, and are at least 18 years of age.

Key exclusion criteria: pregnant women or women of childbearing age, currently taking medications for weight loss, enrolled in another clinical trial, or planning on having bariatric surgery. Any patient who is taking medication prescribed by a physician for depression, anxiety, or any other psychiatric disorder will be excluded. Patients on glucocorticoids in excess of Prednisone 7.5 mg or equivalent will also be excluded.

Study Design: All patients who pass screening will be administered the IPQ Test®[6]. This test stratifies patients on how they use their imagination, an important factor necessary to reach their goals. This is predictive of their potential to "persist" toward agreed upon goals. Patients will be divided into groups as follows: (Raw score 49-96 = high responders; Raw score 0-48 = Low responders).

Ultimately, subjects will be divided into four groups: The assignment of "high" versus "low" responders will be based on the results of the IPQ® test. Subjects will then be randomly assigned to intervention versus control in a 1:1 fashion. Optimally, there should be equal numbers in each group; however, the group sizes may be unequal depending on the relative proportions of high versus low responders. The four groups will be as follows:

Group I (high responders) will receive self-hypnosis using the GIFT™ (Goal Image Focusing Technique)[7] as the main means of autosuggestion and self/group motivation to lose weight.

Group II (low responders) will receive self-hypnosis (without the GIFT™ system) and self/group motivation to lose weight.

Group III (high responders) will receive standard nutrition, diet, and exercise counseling by a CDE (Certified Diabetes Educator) to serve as a control group for Group I.

Group IV (low responders) will receive standard nutrition, diet, and exercise counseling by a CDE (Certified Diabetes Educator) to serve as a control for group II.

Study Design

Study Type:
Interventional
Actual Enrollment :
74 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Self-hypnosis for Weight Loss in Type 2 Diabetics
Study Start Date :
Jul 1, 2013
Actual Primary Completion Date :
Apr 1, 2015
Actual Study Completion Date :
Apr 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Self-hypnosis

Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.

Behavioral: Self-hypnosis
Self-hypnosis

Active Comparator: CDE training

Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.

Behavioral: CDE training
standard CDE training for an obese diabetic

Outcome Measures

Primary Outcome Measures

  1. Change in weight (BMI) [one year]

    Comparison of subject's weight (BMI) from screening visit to last study visit.

Secondary Outcome Measures

  1. Waist circumference [One year]

    change in waist circumference from screening visit to last study date

  2. hemoglobin A1c [one year]

    change in Hgb A1c from screening to last study visit

  3. fasting glucose [one year]

    change in fasting glucose from screening visit to last study visit

  4. High versus low imagery [one year]

    Comparison of subjects who scored high (>=48) or low (<= 47) on the IPQ questionnaire which was administered at the screening visit to all subjects. IPQ test can be found here Harte, Richard and Coller, Alan R. The Harte Coller IPQ® Inventory, Experimental Form E, New York/ The Harte Center for Hypnosis, 1986.

  5. Compliance [one year]

    Assess whether self-reported adherence with the treatment (self-hypnosis or CDE) influenced degree of weight loss

  6. Reproducibility of IPQ [one year]

    Compare results of IPQ test administered at screening with identical test administered at final study visit one year later. To assess how many subjects changed categorization between high (>=48) or low (<=47) responders. Information on IPQ can be found here: Harte, Richard and Coller, Alan R. The Harte Coller IPQ® Inventory, Experimental Form E, New York/ The Harte Center for Hypnosis, 1986.

  7. Degree of weight loss in obese versus overweight [one year]

    Determine if starting BMI influenced degree of weight loss.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of Type 2 Diabetes

  • BMI greater than 25

Exclusion Criteria:
  • pregnant women of of childbearing age

  • currently taking weight loss medications

  • enrolled in another clinical trial

  • currently taking medications for depression or anxiety

  • currently taking Prednisone >7.5 mg day

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Levenson, David I., M.D.

Investigators

  • Principal Investigator: David I Levenson, MD, East Coast Medical Associates

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
David I. Levenson, MD, PI, Levenson, David I., M.D.
ClinicalTrials.gov Identifier:
NCT02769585
Other Study ID Numbers:
  • 1
First Posted:
May 11, 2016
Last Update Posted:
May 13, 2016
Last Verified:
May 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by David I. Levenson, MD, PI, Levenson, David I., M.D.
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 13, 2016